A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease
Latest Information Update: 27 Jul 2022
At a glance
- Drugs Cinpanemab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Biogen
- 21 May 2021 Status changed from active, no longer recruiting to discontinued.(study did not meet its primary outcome measure)
- 24 Mar 2020 Planned End Date changed from 13 Aug 2021 to 6 Jul 2021.
- 24 Mar 2020 Planned primary completion date changed from 13 Aug 2021 to 6 Jul 2021.